Antagonistic analogs of growth hormonereleasing hormone (GHRH) are being synthesized in our laboratory for various clinical applications, including treatment of certain endocrine disorders and insulin-like growth factor I-dependent tumors. To evaluate the endocrine effect of these GHRH antagonists, a sensitive dynamic in vitro system has been developed. The concentration causing 50% inhibition (IC50) of the standard GHRH antagonist human [N-Ac-Tyr',DArg2]GHRH-(1-29)-NH2 is 4.5 x 10-8 M in our dispersed pituitary cell superfusion system. This value is 11 times less than that measured in earlier static pituitary cell cultures. This reliable dynamic system is simple, fast, and inexpensive and not only makes it possible to obtain quantitative data on the Inhibitory capacity of the antagonists but also provides information about the intrinsic GHRH activity of the analog. The dynamic interactions of the GHRH antagonist, the GHRH receptors, and GH release can also be evaluated by this superfusion system. The pulsatile GH release induced by 10-9 M human GHRH-(1-29)-NH2 was inhibited by two modes of application, preincubation and simultaneous administration of the GHRH antagonist (10-9 to 10-6 M). The reduction in GHRH-stimulated GH response was more pronounced when the cells were preincubated with the antagonist prior to GHRH infusion than for simultaneous application. The inhibitory effect of the antagonist was dose-dependent, temporary, and of the competitive type. GH release induced by nonspecific stimulus (100 mM potassium chloride) was not influenced by the GHRH antagonist. This sensitive dynamic in vitro system appears to be a suitable method for screening the biological activity of various GHRH antagonists and eliminates the drawbacks of static pituitary cell culture.
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Since the isolation and characterization of growth hormonereleasing hormone (GHRH) (1, 2) , various GHRH antagonistic analogs have been synthesized (3) (4) (5) (6) (7) (8) (9) (10) . These analogs are essential for the study of the mechanism of action of GHRH and may also be important in clinical application for endocrine disorders and insulin-like growth factor I-dependent tumors (11) (12) (13) A modified version of the original in vitro bioassay using surviving rat pituitaries (14) has been used to measure the hormone-releasing and inhibiting potency of several hypothalamic releasing and inhibiting hormones (15 (16, 17) . To eliminate the drawbacks of the static method, we used a modified dynamic in vitro system, the principles of which were described earlier (18) (19) (20) (21) . In our dispersed pituitary cell superfusion system, the tissue culture medium is perfused continuously. The test material can be applied in a more physiological pulsatile way. The dynamics of hormone response and the changes in the responsiveness can also be analyzed. (3) was reported to inhibit the GHRH-stimulated adenylate cyclase activity in rat pituitary cells with low potency in the micromolar range (4) and suppress the GHRHinduced GH release with a high IC50 value (-5 x 1O-7 M) in static pituitary cell culture (6, 7) . This analog was also reported to block endogenous GHRH activity after injection in the rat (22, 23) . We used this GHRH analog as the standard antagonist to compare the sensitivity of our system with that of static methods. The peptide was assayed for its intrinsic activity to release GH and for its capacity to antagonize the release of GH induced by 10-9 M 
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Proc. Natl. Acad. Sci. USA 90 (1993) 2147 air/5% CO2 and used as the culture medium. The medium was pumped at a flow rate of 0.33 ml/min. After an overnight recovery period, in which the baseline became stabilized and the cells regained their full responsiveness, the samples were infused through a four-way valve. First, the system was standardized with 3-min exposures to 10-9 M GHRH. The test materials were infused at various concentrations for 3-12 min (one to four fractions) at 30-min intervals. The pituitary cells were extracted by elution with 0.01 M hydrochloric acid at the end of the experiment to determine the total immunologically detectable GH content.
RIA. Rat GH levels in aliquots of undiluted and diluted superfusion samples were determined by double-antibody RIA. The antiserum (a-rGH S-5) and the hormone (rGH RP-2) for GH RIA were provided by the National Hormone and Pituitary Program of the National Institute of Diabetes and Digestive and Kidney Diseases.
Statistical Analysis. The results of RIA were analyzed with a computer program developed in our institute (20) . The net integral value (NET INT) is the difference between the total area under the peak and the area under the baseline along the peak, representing the net amount oftropic hormone secreted in response to stimulus. A linear-logarithmic regression analysis of the trailing edge of the peak provides data on the biological half-time of the response (T50). The Intrinsic Activity of GHRH Antagonist. [N-Ac-Tyrl,DArg2IhGHRH-(1-29)-NH2 was infused alone at concentrations of 10-9 to 10-6 M for 12 min. The antagonist given in these large doses did not reduce the basal GH secretion but paradoxically caused a weak dose-dependent increase in hormonal production (Fig. 2, responses C, E, and G) . This intrinsic activity of GHRH antagonist is expressed as the ratio of the NET INT ofGH response after GHRH antagonist infusion at concentrations tested and the NET INT of GH response after GHRH administration (10-9 M) ( Table 1) . The same elevation ofbasal GH secretion was observed when the GHRH antagonist was preincubated in the next antagonistic tests (Fig. 2, responses T, L, and 0) .
Inhibitory Test Using Preincubation with GHRH Antagonist. The cells were preincubated with 10-9 to 10-6 M [N-Ac-Tyr1,D-Arg2]hGHRH-(1-29)-NH2 for 9 min (Fig. 2, responses T, L, and 0) and then immediately exposed to a mixture of this GHRH antagonist and 10-9 M GHRH for an additional 3 min (Fig. 2 , responses J, M, and P). After 30 min, the duration of the inhibitory effect of GHRH antagonist on the responsiveness of GH cells was evaluated by the infusion of 10-9 M GHRH (Fig. 2, responses K, N, and Q was infused for 3 min at 10-9 to 10-6 M concentration simultaneously with 10-9 M GHRH (Fig. 3, responses C , E, and G). The duration of the inhibitory effect was evaluated after 30 min by the infusion of 10-9 M GHRH (Fig. 3 tion. We infused 100 mM potassium chloride for 3 min, which caused a fast short GH response similar to the effect of GHRH (Fig. 3, responses I , J, and L). The possible interaction between the GHRH antagonist (10-6 M) and potassium chloride (100 mM) was evaluated by simultaneous infusion of these compounds for 3 min. GHRH antagonist, even at a concentration of 10-6 M, did not influence the potassiumevoked GH response (Fig. 3, response K) .
DISCUSSION
In vitro assays have been used for screening the biological activity of hypothalamic hormones (such as GHRH) prior to their in vivo evaluations. Since the description of the GHRH antagonist [N-Ac-Tyr1,D-Arg2]hGHRH-(1-29)-NH2 (3, 4) , the inhibitory capacity of other GHRH antagonist analogs (3-10) has been evaluated only in static pituitary cell culture so far (16, 17) . However, the static method is not really adequate when the dynamics of the response have to be I, 3 analyzed or when more complex approaches are required, like testing of interactions or antagonistic activity (20) .
To avoid the drawbacks of static organ culture, we used a dynamic in vitro assay to test GHRH antagonist activity, modifying earlier methods (18) (19) (20) (21) . The sensitivity of our superfusion method is significantly higher than that of static (6, 7) . This variation can be explained by the difference between the two systems. In static organ culture, during the 3-h incubation with GHRH and GHRH antagonist, the responsiveness of GH cells can be influenced. In contrast, in our method, when we apply pulsatile GHRH infusions for 3 min at 30-min itervals, the responsiveness of GH cells does not change, since equal GH responses could be observed after GHRH exposures and the GH release returned to baseline levels before the next GHRH infusion (Fig.   1 ). In addition, hormones and other metabolic products released into the incubated medium can modify the metabolism of cells in static organ culture. Both the materials tested and the secreted hormones and other metabolic products could be digested by the proteolytic enzymes during the long incubation period. In the superfusion system, the continuous flow of medium through pituitary cells eliminates these factors.
The GHRH antagonist did not decrease the basal GH production in our system. This basal GH secretion seems to be independent of the specific GH releasing mechanism and caused by nonspecific electrochemical events on the cell membrane (20) . GHRH antagonist increased the GH release in a dose-dependent manner (Fig. 2) . This increase can be considered as intrinsic activity ( (3-10, 16, 17) . This lack of preincubation could partially explain the reduced sensitivity of earlier static organ culture. The inhibition of GHRH-stimulated GH release after GHRH antagonist infusion was temporary, dose-dependent, and competitive. The antagonist influenced the specific GH release mechanism, apparently acting only at the level of the receptors, since it did not modify the GH releasing potency of a nonspecific stimulus such as potassium, which causes membrane depolarization independently of GHRH receptors (20) (Fig. 3) .
In conclusion, we developed a sensitive dynamic in vitro system for testing antagonistic activity of synthetic inhibitory analogs of GHRH. This method is also suitable for testing the dynamics of inhibitory effects of some long-lasting GHRH antagonists and for obtaining data on interactions between GHRH antagonists and GHRH receptors.
